Boehringer Ingelheim expands its Business with Biosimilars

Ingelheim, September 26, 2011 - As part of its corporate strategy Boehringer Ingelheim announced today to establish a new separate business for the development and commercialization of own biosimilars.

Boehringer Ingelheim started more than 30 years ago as a pioneer in biopharmaceuticals with the development and manufacturing of biopharmaceutical therapeutics. Today Boehringer Ingelheim Biopharmaceuticals is one of the leading companies in this field straight following its strategy to serve best in class development and manufacturing for its clients and Boehringer Ingelheim itself.